^
    2d
    Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • Sulanda (surufatinib)
    2d
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (clinicaltrials.gov)
    P2, N=39, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4d
    Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma. (PubMed, Sci Rep)
    Subsequently, we validated our findings using the STAT1 inhibitor fludarabine or the NK cell-depleting agent Asialo GM1. Furthermore, combination therapy remodeled the tumor microenvironment by reducing CA IX (hypoxia marker), CD31 (angiogenesis marker), and α-SMA (stromal activation marker) expression (p < 0.05). Apatinib enhances the efficacy and responsiveness of PD-1 inhibition via the STAT1/NK axis, while the combination therapy remodels the tumor microenvironment to potentiate anti-tumor effects.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD31 (Platelet and endothelial cell adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    AiTan (rivoceranib) • fludarabine IV
    7d
    Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Sulanda (surufatinib)
    8d
    A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=423, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    8d
    Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） (clinicaltrials.gov)
    P2, N=30, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed
    Trial completion
    |
    AiTan (rivoceranib)
    9d
    Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis. (PubMed, Anticancer Drugs)
    This study elucidates a novel HDAC1/HIF1α/CA9 axis through which Apatinib induces ferroptosis. Targeting this pathway offers translational potential for overcoming Apatinib resistance in GC therapy.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CA9 (Carbonic anhydrase 9) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • HDAC1 (Histone Deacetylase 1)
    |
    AiTan (rivoceranib)
    10d
    ZSPAC-17: Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (clinicaltrials.gov)
    P4, N=350, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • Real-world evidence
    |
    Sulanda (surufatinib)
    11d
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, Eli Lilly and Company | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate
    14d
    Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med)
    Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • Sulanda (surufatinib)
    14d
    A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Not yet recruiting, Ottimo Pharma Limited
    New P1/2 trial
    15d
    Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer. (PubMed, JAMA Netw Open)
    The angiogenesis inhibitors indicated for mCRC in France (ie, bevacizumab, aflibercept, ramucirumab, and regorafenib) were considered. No associations were found with either recency or cumulative duration of exposure, regardless of the exposure estimation method. In this case-control study of arterial dissections or aneurysms in patients receiving targeted therapy for mCRC, the lack of association with angiogenesis inhibitor exposure was reassuring, given the established benefits of these drugs, particularly bevacizumab, for this indication.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Stivarga (regorafenib) • Cyramza (ramucirumab)